Buy Rating Affirmed on Rigel’s Consistent Performance and Growth Prospects

1d ago, source:

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Rigel (RIGL – Research Report), retaining the price target of $4.00. Yigal ...

Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy

10d ago, source:

Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. Check out RIGL stock's ...

Rigel Pharmaceuticals, Inc.

4mon ago, source: CNN

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.

Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

2d ago, source: Finanznachrichten

May 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE ® (fostamatinib ...

Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...

1d ago, source:

Explore key financial outcomes and strategic directions from Rigel Pharmaceuticals' first quarter earnings call of 2024.

Rigel Pharmaceuticals Inc RIGL

1y ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rigel Pharmaceuticals Inc.

15d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

1d ago, source:

Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak ...